Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    An Enquiry

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Relacorilant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corcept to present late-breaking data from Rosella trial at ASCO Meeting
    Corcept to present late-breaking data from Rosella trial at ASCO Meeting

    23 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250422468615/en/CORCEPT-TO-PRESENT-LATE-BREAKING-DATA-FROM-PIVOTAL-PHASE-3-ROSELLA-TRIAL-OF-RELACORILANT-IN-PLATINUM-RESISTANT-OVARIAN-CANCER-AT-ASCO-2025

    BUSINESSWIRE
    23 Apr 2025
    Share Share
    Corcept Starts Trial in Platinum-Resistant Ovarian Cancer
    Corcept Starts Trial in Platinum-Resistant Ovarian Cancer

    07 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250407805321/en/Corcept-Initiates-Trial-of-Relacorilant-Plus-Nab-Paclitaxel-and-Bevacizumab-in-Patients-With-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    07 Apr 2025
    Share Share
    FDA Files Corcept's NDA for Relacorilant in Hypercortisolism
    FDA Files Corcept's NDA for Relacorilant in Hypercortisolism

    03 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250303227690/en

    BUSINESSWIRE
    03 Mar 2025
    Share Share
    Corcept Submits NDA for Relacorilant in Hypercortisolism
    Corcept Submits NDA for Relacorilant in Hypercortisolism

    30 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241230947567/en

    BUSINESSWIRE
    30 Dec 2024
    Share Share
    Corcept’s Relacorilant Ph 3 Shows Cardiometabolic Improvements
    Corcept’s Relacorilant Ph 3 Shows Cardiometabolic Improvements

    16 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241216461773/en

    BUSINESSWIRE
    16 Dec 2024
    Share Share
    Corcept's GRACE Relacorilant Hypercortisolism Phase 3 Data Presented
    Corcept's GRACE Relacorilant Hypercortisolism Phase 3 Data Presented

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892174/0/en/Corcept-Therapeutics-Announces-Presentations-of-Results-of-Pivotal-Phase-3-GRACE-Trial-Evaluating-Relacorilant-in-Patients-with-Hypercortisolism-Cushing-s-Syndrome.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share